The entero-insular axis in type 2 diabetes - Incretins as therapeutic agents

Experimental and Clinical Endocrinology and Diabetes

Volumn 109, Issue SUPPL. 2, 2001, Pages

  Creutzfeldt, W ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Dipeptidylpeptidase IV inhibition; Enteroinsular axis; GIP; GLP 1 7 36 amide; GLP 1 for treatment of diabetes mellitus; Incretin effect

Indexed keywords

ANTIDIABETIC AGENT; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; INCRETIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFICACY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT INDICATION;

ANIMALS; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HUMANS; INTESTINES; ISLETS OF LANGERHANS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 0034967893     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18589     Document Type: Article

References (122)

1. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane
2. Contributions à l'étude des variations physiologiques de la sécrétion interne du pancreas: Relations entre les sécrétions externe et interne du pancréas
3. Studies on the physiology of secretin
4. Über den blutzuckerwirksamen Stoff in Sekretinextrakten
5. Über das insulinotrope Hormon der Darmschleimhaut (Duodenin). Naunyn
6. Is a duodenal hormone involved in carbohydrate metabolism?
7. New interpretation of oral glucose tolerance
8. Plasma insulin responses to oral and intravenous glucose administration
9. Stimulation of release of insulin by an extract of intestinal mucosa
10. Plasma insulin responses to oral and intravenous glucose: Studies in normal and diabetic subjects
11. Oral glucose decreases hepatic extraction of insulin
12. Discrepancy between plasma C-peptide and insulin response to oral and intravenous glucose
13. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes
14. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: Interactions with glucose, phenylalanine, and cholecystokinin-8
15. Entero-insular axis
16. The incretin concept today
17. Neural control of the endocrine pancreas
18. Pancreatic neuroendocrinology: Peripheral neural mechanisms in the regulation of the islets of Langerhans
19. Autonomic nervous control of pancreatic endocrine secretion
20. Peripheral insulin in response to the sight and smell of food
21. Effect of cephalic-vagal stimulation on insulin, gastric inhibitory polypeptide, and pancreatic polypeptide release in humans
22. The enteral insulin-stimulation after Whipple's operation
23. Studies of the entero-insular axis following pancreas transplantation in man: Neural or hormonal control?
24. Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation
25. The Enteroinsular Axis
26. Cholecystokinin receptor antagonist loxiglumide modulates plasma levels of gastroentero-pancreatic hormones in man
27. Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans
28. Regulation of pancreatic endocrine function by cholecystokinin: Studies with MK-329, a nonpeptide cholecystokinin receptor antagonist
29. The role of endogenously released cholecystokinin (CCK) in determining postprandial insulin levels in man: Effect of loxiglumide, a specific DDK receptor antagonist
30. Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans
31. A gastric inhibitory polypeptide. I. The amino acid composition and the tryptic peptides
32. A multiparameter study on the action of preparations containing cholecystokinin pancreozymin
33. Stimulation of insulin secretion by gastric inhibitory polypeptide in man
34. Gastric inhibitory polypeptide. Its physiological release and insulinotropic action in the dog
35. Effects of gastric inhibitory polypeptide present in impure pancreozymin-cholecystokinin on plasma insulin and glucagon in the rat
36. Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP)
37. Electron immunocytochemical evidence for the K-cell. Localization of gastric inhibitory polypeptide (GIP) in man
38. A novel form of gastric inhibitory polypeptide (GIP) isolated from bovine intestine using a radioreceptor assay. Fragmentation with staphylococcal protease results in GIP1 - 3 and GIP4 - 42, fragmentation with enterokinase in GIP1 - 16 and GIP17 - 42
39. The isolation and sequencing of human gastric inhibitory polypeptide (GIP)
40. Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor
41. Decreased GIP secretion through impairment of absorption
42. Stimulation of insulin release in isolated rat islets by GIP in physiological concentrations and its relation to islet cyclic AMP content
43. The insulinotropic action of gastric inhibitory polypeptide in perfused isolated rat pancreas
44. Effect of graded intraduodenal glucose infusions on the release and physiological action of gastric inhibitory polypeptide
45. Evidence for and characterization of specific high affinity binding sites for the gastric inhibitory polypeptide in pancreatic beta-cells
46. Cell and molecular biology of the incretin hormones glucagonlike peptide-I and glucose-dependent insulin releasing polypeptide
47. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain
48. Postprandial stimulation of insulin release by glucose -dependent insulinotropic peptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat
49. Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 (7 - 36 amide) infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects
50. Gut hormones and diabetes mellitus
51. Incretin effects of increasing glucose loads in man calculated from venous insulin dan C-peptide responses
52. Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution
53. Preserved incretin activity of GLP-1 [7 - 36 amide] but not of synthetic human GIP in patients with type-2-diabetes mellitus
54. Insulinotropin: Glucagon-like peptide-1 (7 - 36) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas
55. Pancreatic and intestinal processing of proglucagon in man
56. Glucacon-like peptide-1 but not glucagon-like peptide 2 stimulates insulin release from isolated rat pancreatic islets
57. Glucagon-like peptide-1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line
58. Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut
59. Glucagon-like peptide-1 7 - 36: A physiological incretin in man
60. Effect of glucagon-like peptide- 1 on insulin secretion
61. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig an man
62. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut
63. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas
64. Stimulation of truncated glucagon-like peptide-1 release from the isolated perfused canine ileum by glucose absorption
65. Regulation of intestinal pro-glucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop
66. Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides
67. Glucagon-like-peptide-1 secretion from canine L-cells is increased by glucose-dependent-insulinotropic peptide but unaffected by glucose
68. Additive insulinopropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-l-(7 - 36) amide infused at near-physiological insulinotropic hormone and glucose concentrations
69. Receptors for glucagon-like peptide-1 (7-36) amide on rat insulinoma derived cells
70. Expression cloning of the pancreatic ß cell receptor for the gluco-incretin hormone glucagon-like peptide 1
71. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9 - 39) an antagonist of the receptor
72. Glucagon-like peptide-1 (7-36) amide: Characterization of the domain responsible for binding to its receptor on rat insulinoma RINm 5F cells
73. Structure/activity characterization of glucagon-like peptide-1
74. Exendin-4 is a high potency agonist and truncated exendin-(9 - 39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells
75. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide
76. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
77. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans
78. Synergistic stimulatory effect of glucagon-like peptide-1 (7-36) amide and glucose-dependent insulin-releasing polypeptide on the endocrine rat pancreas
79. Comparison of the effect of GIP and GLP-1 (7-36 amide) on insulin release from rat pancreatic islets
80. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene
81. Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mic with disruption of GLP-1 receptor signaling
82. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1
83. Glucagon-like peptide 1 (GLP-1): A potent gut hormone with a possible therapeutic perspective
84. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36] in the fasting state in healthy subjects
85. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
86. Subcutaneous glucagon-like peptide 1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects
87. Exaggerated secretion of glucagon like peptide-1 (GLP-1) could cause reactive hypoglycaemia
88. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 (7-36 amide) after subcutaneous injection in healthy volunteers. Dose-response-relationships
89. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach
90. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus
91. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36) amide in Type 1 diabetic patients
92. Effects of GLP-1 on gastric emptying, antropyloric motility, and transpyloric flow in response to a nonnutrient liquid
93. Truncated GLP-1 (proglucagon 87-107-amide) inhibits gastric and pancreatic functions in man
94. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (non-insulin-dependent) diabetic patients
95. Differential effects of subcutaneous GLP-1 on gstric emptying, antroduodenal motility, and pancreatic function in men
96. Glucagon-like peptide 1 inhibition of gastric emptying outweighs ist insulinotropic effects in healthy humans
97. Is glucagon-like peptide 1 an incretin hormone?
98. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal
99. GLP-1 does not acutely affect insulin sensitivity in healthy man
100. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats
101. Glucagon-like peptide- 1 promotes satiety and suppresses energy intake in humans
102. Glucagon-like peptide-1 is a physiologic regulator of food intake in humans
103. Insulinotropic action of glucagon like peptide-1-(7-36) in diabetic and nondiabetic subjects
104. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure
105. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients
106. Normalization of insulin response to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM
107. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
108. Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1 (7-36) amide in non-insulin dependent diabetes mellitus
109. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes
110. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, and peptide histidine methionine and is responsible for their degradation in human serum
111. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in the anesthetized pig
112. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes
113. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide
114. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats
115. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity
116. Derivatives of glucagon-like peptide-1 suitable for once daily administration
117. Insulinotropic effect of exendin-4 in humans
118. AC2993 (synthetic exendin-4) lowered postprandial plasma glucose concentrations in people with type 2 diabetes
119. Glugacon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose)
120. Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve
121. Delayed gstric emptying occurs following acarbose administration and is a further mechanism for ist antihyperglycaemic effect
122. Prolonged and enhanced secretion of glucagon-like peptide 1 (7 - 36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in type 2 diabetic patients